Daniel A. Pollyea, MD, MS, discusses how far the field of acute myeloid leukemia has come in the last 1 to 2 years.
Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses how far the field of acute myeloid leukemia (AML) has come in the last 1 to 2 years.
For years, this patient population had limited treatment options with poor outcomes, according to Pollyea. Over the last few years, there has been a huge acceleration in terms of options available for these patients.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More